number of "milky spots", which are considered to act as a gate through which small particles are absorbed from the peritoneal cavity into the subperitoneum (16).
ANTICANCER RESEARCH 26: 4603-4606 (2006)
Treatment of Peritoneal Carcinomatosis Using Carboplatin-loaded Hydroxyapatite Particles HIROMITSU TAKEYAMA1, NORIAKI MOHRI1, ISAMU MIZUNO1, YOSHIMI AKAMO1, HIROZUMI SAWAI1, TADAO MANABE1, TOSHIHISA YOTSUYANAGI2 and SATOSHI NAKAMURA3 1Department
of Gastroenterological Surgery, Nagoya City University, Graduate School of Medical Sciences, Kawasumi-1, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601; 2Faculty of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabedori, Mizuho-ku, Nagoya, 467-0027; 3Institute for Medical and Dental Engineering, Tokyo, Medical and Dental University, 2-3-10 Surugadai, Kanda, Chiyoda-ku, Tokyo, 101-0062, Japan
Abstract. The anti-tumor effects and tissue distribution of carboplatin (CBDCA) incorporated into hydroxyapatite (HAP) particles was studied. Materials and Methods: Seven days after the intraperitoneal (i.p.) implantation of AH130 tumor cells into Donryu rats, the animals were randomized into four groups: group I was treated with saline i.p.; Group II, with CBDCA i.v.; group III with CBDCA i.p.; and group IV with HAP-CBDCA i.p. Results: The survival rate of group IV was better than that of the other groups (p
